Trastuzumab brengitecan vs Zanidatamab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Biliary Tract Cancer
Shared mechanism: HER2 · full Biliary Tract Cancer pipeline
Trastuzumab brengitecan
Developed by Sichuan Baili Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07606599 (registry estimate)
No aligned efficacy figure on record for this race.
Zanidatamab
Marketed by Jazz Pharmaceuticals and partners
NCT04466891 · Phase 2 · completed
This was a single-arm, open-label study of 87 participants, so responses cannot be directly compared with placebo or another treatment. The objective-response primary endpoint was met in the reported analysis, but the lack of randomization, blinding, and a comparator limits the strength of the evidence.
Next expected readout: June 2028 · NCT07841873 (registry estimate)
Reported efficacy
Confirmed Objective Response Rate (ORR): Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) (met)
Result source: NCT04466891
Results for Biliary Tract Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Trastuzumab brengitecan: no structured comparison results are available for Biliary Tract Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Trastuzumab brengitecan's landscape · Zanidatamab's landscape